iBio reveals preclinical data for IBIO-600 and Activin E antibody combo with semaglutide

iBio, Inc.

IBIO-600 NHP study: half-life 40-52 days, potential human half-life up to 130 days; dose-dependent lean mass increase and fat reduction.
Activin E monotherapy in obese mice: ~4% weight loss, 18% fat reduction vs placebo after two weeks.
Activin E + semaglutide combination: 34% total weight loss (9% above semaglutide alone), 72% body fat reduction by DEXA.
Both candidates target obesity and cardiometabolic diseases; IBIO-600 is anti-myostatin, Activin E induces fat-selective weight loss.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.